US/UK/Canada

Share

Links

Quotes

In the past, resistance mechanisms were usually thought of as static. Our study demonstrates, conversely, that a binary designation of resistance may oversimplify cancer’s true biology. These genetic mutations can fluctuate over time, and some patients can harbor more than one mutation.
Zofia Piotrowska, MD, lead author of the study
In an era where cancer treatment is increasingly personalized to the biology of each individual patient, our findings highlight the importance of molecular testing and the need for improved, noninvasive methods for serial testing.
Zofia Piotrowska, MD
In the past year, the Vice President’s moonshot initiative has brought critical attention to the need for greater collaboration and innovation in cancer research, and we are invigorated at the prospect of radiation oncology being an instrumental component of future progress. Moving forward, we must maintain the focus on advancing both the science and practice of cancer care while aligning our efforts to move Congress to authorize the $700 million requested by the President for cancer research initiatives. Substantial, predictable financial support is essential to sustain the fight to eradicate cancer.
Bruce G. Haffty, MD, FASTRO, past Chair of ASTRO’s Board of Directors
The goal of ASTRO’s 2016 Annual Meeting is to highlight the latest scientific and technological advances while emphasizing the importance of radiation oncology in providing value to cancer patients through cure and palliation.
ASTRO President David C. Beyer, MD, FASTRO
Pick a time period -
Tags ( Active)

Clinical trials and emerging research in radiation oncology to be featured at ASTRO’s Annual Meeting in Boston

Press program will highlight innovations in cancer care from 15 leading studies in five news briefings held live on-site and via webcastThe American Society for Radiation Oncology (ASTRO) announced today the press program for its 58th Annual Meeting, which includes multiple reports from phase III clinical trials, researchers from leading institutions in the U.S. and abroad, and examinations of a range of cancer types and patient populations. Researchers will share their findings in a series of briefings held on-site at the Boston Convention & Exhibition Center and webcast to registered

ASTRO awards $275,000 in grants to support early career researchers in radiation oncology

The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of $275,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology Research Seed Grants. All winners will be recognized at ASTRO’s 58th Annual Meeting, September 25-28, 2016, at the Boston Convention and Exhibition Center. “ASTRO awards and grants support work in the field of radiation and cancer biology, radiation physics and translational research,” said ASTRO

Brachytherapy pioneer Haakon Ragde, MD, chosen as ASTRO 2016 Honorary Member

The American Society for Radiation Oncology (ASTRO) has selected Haakon Ragde, MD, as its 2016 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics. Ragde will be inducted as the 2016 ASTRO Honorary Member during an awards ceremony at ASTRO’s 58th Annual Meeting, September 25-28, 2016, in Boston. The first ASTRO Honorary Membership was awarded in 1989. Ragde is the 33rd physician to be chosen for the honor. “Dr. Ragde is a luminary in the field of

Innovators and leaders in the field of radiation oncology honored with ASTRO Gold Medal awards

Three leaders in radiation oncology, including clinicians and researchers from Duke University, Massachusetts General Hospital and Cedars-Sinai Medical Center, have been named recipients of the American Society for Radiation Oncology (ASTRO) Gold Medal, the highest honor bestowed upon members of the world’s largest radiation oncology society. Benedick A. Fraass, PhD, FASTRO, Christopher G. Willett, MD, FASTRO, and Anthony L. Zietman, MD, FASTRO, will be recognized at an awards ceremony during ASTRO’s 58th Annual Meeting, to be held September 25-28, 2016, in Boston. ASTRO awards its

A shorter radiation therapy schedule can be as effective as a conventional schedule for men with low-risk prostate cancer

RTOG 0415 data indicates treatment delivered over five and one-half weeks results in similar disease-free survival rates as an eight-week scheduleHypofractionated radiation therapy (RT), which is delivered in larger doses over a shorter time period than conventional RT, results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. RTOG 0415 was a phase III study conducted from April 2006 to December

Androgen deprivation therapy for two years after radiation therapy improves disease-free survival in patients with advanced prostate cancer

Study analyzes 15-year follow-up of RTOG 9202A long-term follow-up of RTOG 9202 (Hanks 2004) indicates that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen deprivation (LTAD) therapy after radiation therapy (RT) plus short- term androgen deprivation (STAD) therapy improved disease-free survival (DFS) by 60 percent compared to patients who only received RT plus STAD, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Men with advanced prostate cancer typically receive

Anti-androgen therapy and salvage RT improves overall survival for a prostate cancer recurrence after a prostatectomy

10-year follow up of RTOG 9601 also shows lower incidence of prostate cancer-related death without increase of toxicityProstate cancer patients who face recurrence after radical prostatectomy (RP) have better overall survival rates with a combination of salvage radiation therapy (RT) and 24 months of anti-androgen therapy (AAT) than with RT alone, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Many men with prostate cancer who undergo RP—surgical removal of the prostate—experience recurrence, as evidenced by an

Genomic classifier appears to predict metastasis in prostate cancer patients following prostatectomy

For men with prostate cancer who have had a prostatectomy and salvage radiation therapy (SRT), analyzing their tumor genome provides clues as to whether their cancer will metastasize, therefore enabling clinicians to better personalize treatment options, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Prostate cancer treatment varies based on the severity and stage of the disease, with some patients requiring prostatectomy, which is the surgical removal of the prostate. For those patients who develop elevated prostate-

Hypofractionated radiation therapy may be an acceptable treatment for some patients with localized prostate cancer

Personalizing treatment decisions according to patient baseline status remains important to maintaining long-term quality of lifeLong-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated (HRT) intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality of life outcomes, when compared to conventional radiation therapy (CRT), according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Men diagnosed with prostate cancer have

Patients with intermediate-risk meningiomas who receive postoperative radiation therapy have excellent three-year progression-free survival

First analysis of RTOG 0539 trial also indicates minimal adverse eventsPatients with intermediate meningiomas treated with radiation therapy (RT) after surgery experienced a 96 percent three-year progression-free survival rate and had minimal adverse events, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Meningioma, the most common type of central nervous system tumor, nearly always forms on the meninges—the membranes that surround the brain and spinal cord. Most meningiomas, approximately 75 percent, are benign (

Pediatric patients with ependymoma have favorable outcomes with immediate post-surgical radiation therapy

Large Children’s Oncology Group trial reports five-year event free survivalOutcomes for pediatric patients as young as 12 months old with ependymoma who are treated with immediate post-operative radiation therapy are favorable and consistent based upon the patients’ tumor surgical resection and tumor grade, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting.    The Children’s Oncology Group ACNS0121 trial was a prospective study for childhood ependymoma (EP)— a rare type of brain and spinal cord tumor that arises from the

Use of involved field irradiation therapy for locally advanced esophageal cancer reduces toxicity

For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy (RT) that targets only the involved lymph nodes regions results in less toxicity without causing a statistically significant difference in loco-regional lymph nodal recurrence, distant failure and overall survival rates, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. The American Cancer Society estimates that while esophageal cancer makes up approximately one percent of all cancers diagnosed in the U.S., it is

Advanced cancer patients have better quality of life when radiation therapy and palliative care are coordinated, based on patient-reported feedback

A collaborative, patient reported outcome (PRO)-based approach by palliative care and radiation oncology teams, results in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. The data also showed that through the implementation of rapid palliative radiotherapy that includes shorter, higher doses of radiation therapy, many patients experience pain relief within one week of treatment. Starting in 2012,

Cancer patients with bone metastases undergoing radiation therapy for symptom control have a lower rate of pain flare with steroid use

Results of trial conducted by NCIC Clinical Trials GroupThe steroid dexamethasone reduces radiation-induced pain flare in cancer patients with painful bone metastases, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Patients with cancer that has spread (metastasized) to their bones can experience debilitating bone pain. While radiation therapy (RT) is commonly used to treat patients with bone metastases to lessen this pain, it can also temporarily cause pain flare, a worsening of the pain, in some patients. According

Frequent post-treatment follow-up by advance practice nurses improves care for high-risk head and neck cancer patients

Better symptom management results in fewer emergency room visits and hospital admissionsFor high-risk patients who receive chemoradiation therapy for head and neck cancer, frequent follow-up appointments conducted by advance practice nurses (APN) in a clinical outpatient setting allowed for more intensive symptom management, resulting in fewer post-treatment emergency room visits and hospital admissions compared to historical outcomes, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Treatments such as radiation therapy

Image-guided intensity modulated radiation therapy (IG-IMRT) reduces bowel side effects in cervical cancer patients

For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IG-IMRT) resulted in a 14 percent reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3-D CRT), according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting.  Post-operative pelvic radiation therapy is the current standard of care for many patients with cervical cancer, yet may affect surrounding organs and tissue and be associated with

Lung cancer patients who receive intensity modulated radiation therapy (IMRT) have less inflammation and better tolerance of follow-up chemotherapy

Secondary analysis of NRG/RTOG 0617 compares IMRT to conventional RTPatients with stage III non-small cell lung cancer (NSCLC) who receive intensity modulated radiation therapy (IMRT) have 44 percent fewer cases of severe pneumonitis and improved likelihood of completing consolidative chemotherapy after radiation, compared to patients who receive three-dimensional conformal radiation therapy (3-D CRT), according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. The standard of care for patients with locally-advanced (stage III)

Reduced intensity chemoradiotherapy may be as effective as current standard for patients with HPV-related oropharynx cancer

Patients who received reduced dose experienced less side effectsFor some patients with human papilloma virus (HPV)-related cancer of the tonsils and tongue, reduced intensity radiation therapy (RT) and chemotherapy may be as effective as standard-dose radiation and chemotherapy, and result in less acute side effects, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. The incidence of cancer at the base of the tongue and tonsil is rapidly increasing and thought to be caused by HPV infection. The standard treatment for

Cleveland Clinic nurse receives 2015 ASTRO Annual Meeting Nurses Abstract Award

The American Society for Radiation Oncology (ASTRO) has awarded the 2015 Annual Meeting Nurses Abstract Award to Bridgett Harr, CPN, Cleveland Clinic, Cleveland, for the abstract “Advanced Practice Nurse Follow-up Clinic Reduces Emergency Room Visits and Admissions in High-Risk Patients after Chemoradiation Therapy for Head and Neck Cancer.” The Annual Meeting Nurses Abstract Award honors the highest rated abstract with a nursing designation. Award candidates must be nurses who are the lead author or co-author of an abstract selected for presentation at the 2015 ASTRO Annual Meeting. Ms.

ThriveWell Cancer Foundation to receive ASTRO Survivor Circle grant

The Texas cancer patient support organization will receive an $8,500 awardThe American Society for Radiation Oncology (ASTRO) has selected a San Antonio-based cancer patient support group, ThriveWell Cancer Foundation, to receive ASTRO’s 2015 Survivor Circle grant. The organization will receive $8,500 to recognize its efforts and provide direct support for the organization’s work assisting cancer patients and their families. The group will also be in attendance at ASTRO’s 57th Annual Meeting, October 18-21 at the Henry B. González Convention Center in San Antonio. “ASTRO is proud to

Dan’s House of Hope to receive ASTRO Survivor Circle grant

Texas cancer patient support organization receives an $8,500 awardThe American Society for Radiation Oncology (ASTRO) has selected a Houston-based cancer patient support group, Dan’s House of Hope, to receive ASTRO’s 2015 Survivor Circle grant. The organization will receive $8,500 to recognize its efforts and provide direct support for the organization’s work assisting cancer patients and their families. The group will also be in attendance at ASTRO’s 57th Annual Meeting, October 18-21 at the Henry B. González Convention Center in San Antonio. “ASTRO is proud to continue to sponsor the

San Antonio cancer survivor and volunteer will be honored with ASTRO’s 2015 Survivor Circle Award

Cancer survivor and volunteer Vicki Shapiro will be recognized at ASTRO Annual MeetingThe American Society for Radiation Oncology (ASTRO) has selected San Antonio resident and cancer survivor Vicki Shapiro to receive the 2015 Survivor Circle Award. Ms. Shapiro will be presented with the award, including $1,000, at the Awards Ceremony on Tuesday, October 20 at ASTRO’s 57th Annual Meeting at the Henry B. González Convention Center in San Antonio, October 18-21, 2015. The Survivor Circle Award recognizes a cancer survivor who lives in the ASTRO Annual Meeting host city and who has dedicated

ASTRO awards $33,500 in individual grants to 41 researchers presenting at 2015 Annual Meeting

The American Society for Radiation Oncology (ASTRO) has selected 41 recipients to receive a total of $33,500 for the 2015 Annual Meeting Abstract Awards. The awardees will be recognized at ASTRO’s 57th Annual Meeting, October 18-21, 2015 at the Henry B. González Convention Center in San Antonio. “The excellent contribution by top radiation oncologist researchers to the field, as well as to ASTRO’s 57th Annual Meeting, has continued this year with more than 2,800 abstract submissions received,” said ASTRO President Bruce D. Minsky, MD, FASTRO. “These abstracts represent the important work

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media